3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Interventions
Carboplatin
10
Paclitaxel
8
Bevacizumab
7
Cyclophosphamide
6
olaparib
5
niraparib
5
Fulvestrant
4
talazoparib
3
Radiotherapy
3
Gemcitabine
3
Capecitabine
3
veliparib
2
palbociclib
2
eribulin
2
dostarlimab
2
aldesleukin
2
Trastuzumab
2
Specimen Handling
2
Letrozole
2
Drug Therapy
2
Doxorubicin
2
Cisplatin
2
Celecoxib
2
Biopsy
2
Albumin-Bound Paclitaxel
2
tucotuzumab celmoleukin
1
trastuzumab duocarmazine
1
trastuzumab biosimilar HLX02
1
sotigalimab
1
sargramostim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Ovarian Neoplasms
×
Dianhydrogalactitol
×
Clear all
NCT03281681
2019-10-18
REPROVe
Kintara Therapeutics, Inc.
Phase 1/2
Withdrawn